Western Michigan Man Accused Of Shooting, Burying BrotherA 25-year-old man has been arraigned on a murder charge, accused of killing and then burying his brother in Allegan, Michigan.
Perrigo-Elan Deal Takes A Step Forward With Irish High Court ApprovalAllegan-based Perrigo Co. (NYSE:PRGO) and Ireland's Elan Corp. plc (NYSE:ELN) Friday announced that the Irish High Court has approved Perrigo’s pending acquisition of Elan.
Perrigo Updates Note OfferPerrigo Co. (NYSE: PRGO) announced that, in connection with its offer to purchase for cash its 2.950% Notes due 2023, it has received the requisite consents to amend the indenture governing the notes.
Perrigo Confirms Filing For Generic Version Of AcanyaThe Allegan generic drugmaker and store brand health products producer Perrigo Co. (NYSE: PRGO) Wednesday announced that it has filed with the U.S. Food and Drug Administration an Abbreviated New Drug Application for Clindamycin Phosphate and Benzoyl Peroxide Gel 1.2%/2.5% and has notified Dow Pharmasciences, the owner of the New Drug Application, of its filing.
Perrigo Shareholders Approve Elan AcquisitonThe generic prescription drug and store-brand health products maker Perrigo Co. (NYSE: PRGO) announced that its shareholders approved proposals related to its acuqisition of Ireland's Elan Corp. plc at a special meeting Monday.
Perrigo Company Announces Quarterly DividendPerrigo Co. (NYSE: PRGO) announced that its board declared a quarterly dividend of 9 cents per share, payable Dec. 17 to shareholders of record on Nov. 29.
Perrigo Co. Selling $2.3 Billion In Debt To Finance Elan PurchaseThe Allegan generic pharmaceutical and store-brand health products maker Perrigo Co. Ltd., which moved its corporate registration to Ireland earlier this year, said it would offer debt totaling $2.3 billion with maturities in 2016, 2018, 2023 and 2043.
Perrigo Profits, Sales RiseThe generic pharmaceutical and store-brand helath products maker Perrigo Co. (NYSE: PRGO) Thursday reported net income of $111.4 million or $1.18 a share in the first fiscal quarter ended Sept. 28, up from $105.6 million or $1.12 a share in the first fiscal quarter a year earlier. Revenue was $933.4 million, up from $769.8 million a year earlier.
Perrigo Sets Date Of Shareholder Meeting To Approve Elan AcquisitionPerrigo Co. (NYSE: PRGO) announced that it has scheduled a shareholder meeting for Monday, Nov. 18 in connection with Perrigo's proposed previously announced acquisition of Elan Corp. (NYSE: ELN).
Perrigo Announces FDA Final Approval For Generic Version Of Nitrolingual SprayPerrigo Co. (NYSE: PRGO) announced that it has received final approval for its abbreviated new drug application for nitroglycerin lingual spray, 400 mcg/spray, the generic equivalent to Nitrolingual Pumpspray.
Perrigo Company Gets FDA Approval For Generic Zyrtec For Kids, Presents At ConferencesPerrigo Co. (NYSE: PRGO) announced that it has received final approval from the U.S. Food and Drug Administration for its abbreviated new drug application for cetirizine hydrochloride oral solution USP, 1 mg/mL, bubble gum flavored, the store brand equivalent to Children's Zyrtec Allergy Syrup, 1 mg/mL, bubble gum flavored.
Perrigo Sets Records For Quarterly, Annual Sales, ProfitsThe Allegan health and beauty products maker Perrigo Co. (Nasdaq: PRGO) reported record sales and net income for the fourth fiscal quarter and fiscal year ended June 29.